Monopar Therapeutics Inc. (MNPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 23, 2024, by Monopar Therapeutics Inc., a Delaware corporation listed on the Nasdaq Capital Market. The filing reports significant changes to the Company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Kim R. Tsuchimoto will retire effective June 30, 2024, ending her tenure as Chief Financial Officer, principal financial officer, and principal accounting officer. She will continue to serve on the Board of Directors.
- Appointment of New CFO: Karthik Radhakrishnan was appointed to succeed Ms. Tsuchimoto as Chief Financial Officer, principal accounting officer, and principal financial officer, effective July 1, 2024.
- Compensation Package: Mr. Radhakrishnan's appointment includes an annual salary of $384,800, a target bonus of up to 35% of base salary, and stock options to purchase 125,000 shares of Common Stock.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Radhakrishnan's extensive background, including over 20 years of financial strategy and public company experience in the life science sector. He has previously served as CFO for Santalis Pharmaceuticals and Opexa Therapeutics. The Company noted that Mr. Radhakrishnan has been working with Monopar on a consulting basis for over six months prior to this appointment. No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the transition timeline: Ms. Tsuchimoto retires June 30, 2024; Mr. Radhakrishnan starts July 1, 2024.
- Review the vesting schedule for the 125,000 stock options granted to the new CFO (6/48ths on Dec 31, 2024, then monthly).
- Confirm the total annualized compensation cost including the target bonus.
- Check for any subsequent filings regarding the interim financial leadership between June 30 and July 1, 2024.